Research
Hormonal
Aging induces a shift in mesenchymal stem cell lineage toward adipogenesis and away from osteoblastogenesis, driven by low-grade chronic inflammation (LGCI) from Western diets, resulting in osteosarcopenic obesity.
Focus on reducing inflammation through diet (increasing Omega-3s, decreasing Omega-6s) rather than just weight loss, as visceral fat drives the loss of bone and muscle in aging.
ModerateSupportsMEDIUM confidence
the typical Western-type diet is characterized by over-consumption of n-6 polyunsaturated fatty acids (PUFA) coupled with under-consumption of n-3 PUFA resulting in LGCI and, along with the subsequent increased presence of reactive oxygen species, leads to a shift in mesenchymal stem cells (precursors for both osteoblasts and adipocytes) lineage commitment toward increased adipogenesis and suppressed osteoblastogenesis.
Why this rating
The paper is a review citing observational and mechanistic studies, not a single controlled trial.
Source
Aging human body: changes in bone, muscle and body fat with consequent changes in nutrient intake
Pegah Jafarinasabian et al. · Journal of Endocrinology · 2017
DOI 10.1530/joe-16-0603
narrative_reviewCited 314×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Older adults require higher protein intake (1.4-1.6 g/kg/day) than the standard RDA (0.8 g/kg/day) to maintain muscle mass and bone health.Moderate
- Body fat percentages of 32-35% in women are associated with adverse skeletal outcomes, suggesting a lower obesity cutoff for older women than the WHO standard of 40%.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →